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article under the CC BY-NC-ND license (Abstract Background/purpose: The nonvitamin K antagonist oral anticoagulants direct-
thrombin inhibitor dabigatran and the Xa inhibitors rivaroxaban and apixaban are now being
used clinically. The course of the patients on these anticoagulants who underwent tooth
extraction was assessed.
Materials and methods: The medical charts of these patients were investigated. Tooth extrac-
tion was performed while maintaining conventional anticoagulant therapy.
Results: Twenty-three teeth were extracted in 19 patients, including two surgical extractions.
Among the 19 patients, nine patients ingested rivaroxaban, six apixaban, and four dabigatran.
One patient on rivaroxaban showed persistent postoperative bleeding following two surgical
extractions. Mild oozing was observed in five patients (two on rivaroxaban and three on apix-
aban). There was no bleeding episode in the patients on dabigatran.
Conclusion: The patients on rivaroxaban with a prolonged prothrombin time value have a high-
er risk of bleeding, especially undergoing surgical extraction. Apixaban correlates to neither
activated partial thromboplastin time nor prothrombin time values and the countermeasures
should be employed based on the clinical findings.
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Nonvitamin K antagonist oral anticoagulants (NVKAs) have
been developed as an alternative to warfarin. The direct
thrombin inhibitor dabigatran and the Xa inhibitors rivar-
oxaban and apixaban are now being used clinically.
In mega-studies on efficacy for stroke prevention of each
drug [RE-LY (Randomized Evaluation of Long-Term Anti-
coagulation Therapy) study for dabigatran,1 the ROCKET AF
(Rivaroxaban Once Daily Oral Direct Factor Xa Inhibition
Compared with Vitamin K Antagonism for Prevention of
Stroke and Embolism Trial in Atrial Fibrillation) study for
rivaroxaban,2 and the ARISTOTLE (Apixaban for Reduction
in Stroke and Other Thromboembolic Events in Atrial
Fibrillation) study for apixaban3], each drug was compared
with warfarin in atrial fibrillation (AF) patients and found to
be not inferior for prevention of stroke (stroke incidence:
dabigatran 1.53%/y vs. warfarin 1.69%/y; rivaroxaban 1.7%/
y vs. warfarin 2.2%/y; apixaban 1.27%/y vs. warfarin 1.60%/
y), with less hemorrhagic incidence (major bleeding:
110 mg of dabigatran, 2.71%/y vs. warfarin 3.36%/y; apix-
aban 2.13%/y vs. warfarin 3.09%/y; intracranial hemor-
rhage: rivaroxaban 0.5%/y vs. warfarin 0.7%/y).1e3
With regard to metabolism of dabigatran and rivarox-
aban, 70% is excreted by the kidneys and 30% is metabolized
by the liver, followed by excretion in the urine and feces,4,5
while 30% of apixaban is excreted by the kidney and 70%
metabolized by the liver. The peak plasma levels of dabi-
gatran, rivaroxaban, and apixaban were measured after
3e4 hours. The half-life was 11e13 hours for dabigatran,
9e13 hours for rivaroxaban, and 8e15 hours for apixaban.4,5
The dose adjustments based on prothrombin time-
international normalized ratio values, as with warfarin,
are not necessary for these drugs. Therefore, NVKAs are
increasingly being prescribed based on ease of use by both
patients and physicians.
Continued treatment with dabigatran, rivaroxaban, or
apixaban of patients undergoing tooth extraction is rec-
ommended because of a low rate of major bleeding.6
However, there have been few reports of surgery-related
hemorrhagic events and no uniform consensus exists
regarding the management strategy. The purpose of this
case series was to assess the course of patients on dabi-
gatran, rivaroxaban, or apixaban who underwent tooth
extraction. Additionally, a strategy for hemostatic man-
agement is discussed.
Materials and methods
Patients
The present study protocols were approved by the institu-
tional review board and ethics committee of Kyushu Uni-
versity Hospital in compliance with the Helsinki
Declaration. In the present study, the medical charts of
patients were retrospectively reviewed to investigate the
items below.
Tooth extraction was performed in patients on conven-
tional dabigatran, rivaroxaban, or apixaban therapy be-
tween April 2013 and January 2015 at the Special Patient
Oral Care Unit, Kyushu University Hospital.The items investigated were patient characteristics (age
and sex), dose of dabigatran, rivaroxaban, or apixaban,
degree of anticoagulant effects [prothrombin time (PT) or
activated partial thromboplastin time (APTT) value on the
nearest day of tooth extraction], site and number of
extracted teeth, type of tooth extraction (simple or surgi-
cal), time of extraction, and incidence of cases of post-
operative hemorrhage. Furthermore, platelet count, blood
urine nitrogen (BUN), creatinine, aspartate transaminase
(AST), alanine transaminase (ALT), and alkaline phospha-
tase (ALP) were also recorded as laboratory data.
In patients at risk for infective endocarditis, amoxicillin
was administered according to guidelines published by the
Japanese Circulation Society in order to prevent infective
endocarditis.7 As analgesics, either loxoprofen sodium or
acetaminophen was administered as needed.
Tooth extraction and local hemostatic management
Tooth extraction was performed while continuing to main-
tain doses of dabigatran, rivaroxaban, or apixaban. Local
anesthesia was induced using 3% prilocaine (containing
0.054 IU of felypressin). Teeth were extracted in a mini-
mally invasive manner using elevators and forceps, and
inflamed granulation tissue was completely curetted. As for
local hemostatic measures after tooth extraction, extrac-
tion wounds were packed with oxidized cellulose (Surgicel;
Ethicon, Somerville, NJ, USA) or atelocollagen sponge
(Telpulug, Terumo, Tokyo, Japan), and then horizontal
mattress sutures using 4-0 silk were given. When hemostasis
could not be achieved using these procedures, bleeding
points in soft tissue were cauterized using electrocautery,
when necessary. Each patient was asked to bite down on
gauze for 30 minutes for compression, and hemostasis was
confirmed. The wounds were protected by a surgical acrylic
splint with periodontal pack when needed. Sutures were
removed after 1 week. Tranexamic acid mouth wash was
not used, as use of this agent is not approved in Japan.
Likewise, fibrin glue was not used because this agent is not
indicated for use during tooth extraction in Japan.
Results
Patient characteristics
The patients (19) included 17 men and two women, with
ages ranging from 43 years to 86 years. Twenty-three teeth
were extracted, including two surgical extractions (Table
1). Among the 19 patients, nine took rivaroxaban, six
apixaban, and four dabigatran. Most of the teeth were
extracted 4e9 hours after taking the anticoagulant. Two
patients (Cases 15 and 17) received concomitant aspirin
(100 mg/d). All patients receiving rivaroxaban indicated
prolonged PT values, and most patients receiving dabiga-
tran indicated prolonged APTT values. There were no pa-
tients with severe renal or liver dysfunction or
thrombocytopenia.
One patient on rivaroxaban showed persistent post-
operative bleeding, and mild oozing for short durations was
observed in five patients (Table 1). Adequate hemostasis
was achieved in all other patients postoperatively.
Table 1 Patient characteristics.
Case Age
(y)
Sex NVKA Dose (/d) PT (s) APTT
(s)
Extracted
tooth (n)
Extraction
type
Postope rative
bleeding
Extraction
time
Laboratory test
PLT
(104/mL)
BUN
(mg/dL)
Crea
(mg/dL)
AST
(U/L)
ALT
(U/L)
ALP
(U/L)
1 74 Male Rivaroxaban 10 mg UM UM 18 Simple None 10:30 26.0 15 1.40 20 12 UM
2 69 Male Rivaroxaban 15 mg 17.1 53.7 27 Simple Mild 11:30 26.4 13 0.86 20 18 197
3 60 Male Rivaroxaban 10 mg 18.5 46.0 38
37
Surgical
hemisection
Severe 13:00 11.7 44 1.47 21 14 UM
4 86 Female Rivaroxaban 10 mg 16.8 49.5 12,14 Simple Mild 12:30 18.6 21 1.10 18 9 140
5 74 Male Rivaroxaban 15 mg 13.5 UM 46 Simple None 11:30 14.5 13 0.95 70 64 UM
6 84 Female Rivaroxaban 10 mg UM UM 24 Simple None 11:30 11.2 34 1.10 18 9 UM
7 80 Male Rivaroxaban 10 mg 16.2 UM 46 Simple None 13:00 11.1 23 1.08 25 15 336
8 76 Male Rivaroxaban 10 mg 15.9 38.0 46,47 Simple None 16:30 13.4 11 0.91 24 10 UM
9 81 Male Rivaroxaban 10 mg UM UM 17 Simple None 14:00 35.8 16 0.81 43 29 441
10 64 Male Apixaban 5 mg  2 times 12.6 35.7 48 Simple Mild 14:00 21.9 12 0.73 14 15 175
11 76 Male Apixaban 5 mg  2 times 14.7 37.3 37 Simple Mild 17:00 18.7 21 0.92 21 12 211
12 61 Male Apixaban 5 mg  2 times 14.4 36.6 16 Simple None 10:00 17.5 13 0.91 25 23 UM
13 50 Male Apixaban 5 mg  2 times 15.4 UM 34,36 Simple Mild 11:00 12.3 13 0.94 18 13 UM
14 79 Male Apixaban 5 mg  2 times 14.8 40.0 48 Simple None 11:00 15.3 28 0.73 32 21 325
15 83 Male Apixaban 2.5 mg  2 times 16.0 53.0 11 Simple None 14:00 12.4 36 0.87 20 13 220
16 62 Male Dabigatran 110 mg  2 times UM 45.1 47 Simple None 10:30 24.4 19 1.02 37 23 150
17 61 Male Dabigatran 110 mg  2 times UM UM 24 Simple None 10:30 UM UM UM UM UM UM
18 78 Male Dabigatran 110 mg  2 times UM 34.0 13 Simple None 13:00 20.8 24 1.34 28 20 UM
19 43 Male Dabigatran 150 mg  2 times 16.2 48.6 36 Simple None 15:00 10.2 17 0.62 20 11 424
ALPZ alkaline phosphatase (normal limit: 115e359 U/L); ALTZ alanine transaminase (normal limit: 6e30 U/L); APTTZ activated partial thromboplastin time (normal limit: <41.0 s);
ASTZ aspartate transaminase (normal limit: 13e33 U/L); BUNZ blood urine nitrogen (normal limit: 8e22 mg/dL); CreaZ creatinine (normal limit: 0.6e1.1 mg/dL); NVKAZ nonvitamin
K antagonist; PT Z prothrombin time (normal limit: <13.5 s); PLT Z platelet; UM Z unmeasured.
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62 Y. Morimoto et alCase report of the patients with significant
postoperative hemorrhage
Case 3 was a 60-year-old man with pericoronitis of the left
mandibular third molar and extensive dental caries of the
left mandibular second molar, for which extraction of the
left mandibular wisdom tooth and distal root of the left
mandibular second molar was planned. The patient had a
history of AF, corrected transposition of the great arteries,
severe cardiac failure, tricuspid valve prolapse, and chronic
renal failure.
On the day of tooth extraction, the patient took rivar-
oxaban (10 mg) at 7:00 AM and amoxicillin (1.5 g) at noon.
Tooth extraction began at 1:00 PM. For extraction of the
wisdom tooth, the gingiva was incised and reflected, the
crown was removed after being split, and the root was
extracted after removing a small amount of bone. The
distal root of the second molar was extracted by splitting
the tooth at the bifurcation of the root. Then, oxidized
cellulose was inserted, the incisions were sutured with 4-
0 silk suture, hemostasis was confirmed, and a splint was
applied.
At follow-up examination the next day at 11:00 AM, there
was no bleeding from the extraction wounds, but oozing
was noted at 4:00 PM. The oozing continued overnight, and
the patient was again examined at 11:00 AM on post-
operative Day 2. Because oozing from the extraction wound
was persistent, hemostasis was again performed. The splint
was removed and when the sutures and hematoma were
removed, oozing from the extraction cavity was observed.
The oozing did not subside even with gauze compression, so
the bleeding point was coagulated by electrocautery,
oxidized cellulose was again inserted, the surgical site was
resutured, and hemostasis was achieved. Blood test results
at this time were: platelets 11.4104/mL, PT 20.3 seconds,
and APTT 53.7 seconds.
However, mild oozing occurred again, continued though
that night, and gauze was used to bite on as needed. The
patient was subsequently followed up every other day. A
small amount of oozing was noted, but the bleeding finally
stopped by Day 7 with epithelization of the extraction
cavities. Because the physician of the patient recom-
mended continuation of rivaroxaban due to past history of
multiple ischemic strokes, the patient continued to take
rivaroxaban (10 mg) in the mornings during this time.
In Cases 2 and 4 (rivaroxaban), and 10, 11, and 13
(apixaban), slight oozing for approximately 8e12 hours
following simple tooth extraction was observed, requiring
the patients to bite down on gauze for hemostasis. There
was no bleeding episode in the patients on dabigatran.
Discussion
Coagulation tests in patients on NVKAs showed prolongation
of both the PT and APTT. Plasma dabigatran levels showed a
good linear correlation with prolongation of APPT, whereas
plasma rivaroxaban levels showed a good linear correlation
with PT.4,5 However, both PT and APTT are likely to show
poor responsiveness in apixaban.4,5
The patient on rivaroxaban who showed significant
postoperative bleeding (Case 3) had a PT of 18.5 secondson the day of tooth extraction, which was within baseline
values during follow up over a few months. Tooth
extraction was performed 6 hours after the patient took
rivaroxaban, which was presumably past the peak plasma
drug level. Moreover, oxidized cellulose, suturing, and a
splint were used for local hemostasis. The patient again
took rivaroxaban the following day at 7:00 AM, and oozing
began 9 hours after the patient took rivaroxaban. The
time of re-evaluation on postoperative Day 2 for bleeding
was 4 hours after rivaroxaban was taken, the time of the
peak plasma level. Local hemostasis at this time was
difficult despite cauterization by electrocautery, use of
oxidized cellulose, and resuturing, and mild oozing
continued for another 5 days. Bleeding continued even at
the rivaroxaban plasma half-life and trough value times,
thus suggesting that plasma levels of rivaroxaban may
have remained higher than expected due to renal
dysfunction. In a discussion with the physician of the pa-
tient, a decision had been made not to discontinue rivar-
oxaban for the extraction because the patient was at high
risk for thromboembolism. Therefore, measures for local
hemostasis were taken.
In a review paper, an increased risk for bleeding was
reported when the APTT was 1.2e1.5-fold greater than the
normal upper limit in dabigatran, and the PT was 1.2e1.5
greater than the normal upper limit in rivaroxaban.4,8 In
Case 3, the PT value at the time of bleeding (4 hours post-
dose) was 20.3 seconds, 1.5-fold greater than the normal
upper limit. The plasma peak level during that time frame
may have contributed to the bleeding. In the patients with
mild oozing (Cases 2 and 4), PT also exceeded the normal
upper limit by 1.3-fold. Therefore, the risk of bleeding
after tooth extraction increases when PT exceeds the
normal upper limit. However, in the patients on apixaban,
three cases experienced mild oozing (Cases 10, 11, and 13),
suggesting almost normal PT or APTT values. As only the
serum anti-Xa activity indicates the serum agent concen-
tration in patients receiving apixaban, assessment of anti-
Xa activity may be needed when bleeding continues after
tooth extraction.9,10
In the management of patients on NVKAs during surgery,
drug cessation is not necessary for minor surgery when the
risk of bleeding is low. Appropriate measures include
avoiding surgery at a time when the plasma drug level is at
a peak or delaying the time of the next dose.9,10 In patients
with renal dysfunction, drug cessation for longer times has
also been reported.9,10
When a hemorrhagic event occurs, if measurement of PT
(for rivaroxaban) or APTT (for dabigatran) is within the
normal range, plasma levels of rivaroxaban or dabigatran
can be regarded as being in a therapeutic range and local
hemostasis is indicated. If the PT or APTT value is pro-
longed, plasma levels of rivaroxaban or dabigatran can be
regarded as exceeding the therapeutic range and either the
procedure can be delayed for 4e12 hours, or, in the case of
emergency surgery for a life-threatening condition, pro-
thrombin complex concentrate or recombinant activated
factor VII agent can be used to immediately reverse the
effects of anticoagulation.9,10 However, as neither PT nor
APTT correlates with the serum level of apixaban, the same
measures should be taken based on clinical findings when
bleeding occurs.
Tooth extraction and NVKAs 63For dental procedures with a low risk of bleeding,
Mingarro-de-Leon et al11 recommended that, for simple
extraction of three teeth or less and surgery lasting 45
minutes, measures for local hemostasis should be used
without discontinuing NVKAs. For surgery with a higher risk
of bleeding, for example extraction of three or more teeth,
surgery 45 minutes, or head and neck neoplasm surgery,
they recommend discontinuing NVKAs for a few days,
depending on the type of surgery, severity of renal
dysfunction, and risk of bleeding.11 Firriolo et al6 and Breik
et al,12 like Mingarro-de-Leon et al,11 also recommended
local hemostasis without discontinuation of NVKAs in pa-
tients undergoing tooth extraction. However, Breik et al12
reported a case of significant postoperative bleeding
following extraction of 18 teeth while taking dabigatran.12
Based on this report and the present study, surgical tooth
extraction can increase the bleeding risk in patients on
NVKAs. When bleeding is sustained, discontinuation of
these drugs must be considered after discussion with the
physician of the patient and measures for sufficient local
hemostasis must be taken.
In a subanalysis of the RE-LY trial for periprocedural
bleeding, when the last dose of dabigatran was given 49
hours (median) before the procedure, in comparison with
114 hours (median) in patients receiving warfarin, dabiga-
tran and warfarin were associated with similar rates of
periprocedural major bleeding (dabigatran 110 mg: 3.8% vs.
dabigatran 150 mg: 5.1% vs. warfarin 4.6%), and ischemic
stroke or systemic embolism (1.2% vs. 1.5% vs. 1.2%) until 30
days after invasive procedures. Both doses of dabigatran
were associated with a lower risk of perioperative bleeding
or thromboembolism when these were discontinued within
48 hours of surgery.13 However, in the ARISTOTLE trial,
when anticoagulation therapy was discontinued in two-
thirds of patients receiving apixaban or warfarin before
the procedure, the rate of periprocedural major bleeding
(apixaban: 1.62% vs. warfarin: 1.93%) or stroke and sys-
temic embolism (0.35% vs. 0.57%) were also low and similar
between apixaban and warfarin until 30 days after invasive
procedures.14 However, discontinuation of these agents
indicates approximately 0.5e1.5% of thromboembolism
occurrence and conventional anticoagulant therapy with
these drugs should be maintained during tooth extraction as
possible.
In the ROCKET AF trial, when rivaroxaban was dis-
continued for 3 days, the incidence of stroke or noncen-
tral nervous system thromboembolism within 30 days was
6.42/100 patient-years; significantly higher than the inci-
dence when warfarin was discontinued (1.73/100 patient-
years). Therefore, rivaroxaban should be discontinued with
caution in patients undergoing surgery.15 In patients with a
high risk for thromboembolic events, use of low-molecular
weight heparin is recommended.9,10
Based on these findings, the recommendations for pa-
tients on NVKAs who undergo tooth extraction can be
summarized as follows: (1) NVKAs can generally be
continued during tooth extraction, with some patients
experiencing mild oozing postoperatively on the day of
extraction; (2) tooth extraction should be avoided during
the time of peak plasma levels of NVKAs (3e4 hours post-
dose); (3) as surgical tooth extraction can increase the
bleeding risk in patients on NVKAs, sufficient localhemostasis and careful follow up are required; (4) if
bleeding occurs, local hemostasis should be provided after
the time of peak plasma levels; (5) if hemostasis is antici-
pated to be difficult, delaying the next dose of NVKAs or
skipping one dose should be considered and discussed with
the physician of the patient; and (6) caution is necessary in
patients with renal dysfunction or severe liver dysfunction
because NVKA plasma levels may be elevated.
In conclusion, NVKAs can usually be continued in pa-
tients undergoing tooth extraction. However, patients with
a prolonged APTT (for dabigatran) or PT (for rivaroxaban)
value have a higher risk of bleeding, therefore, adequate
local hemostasis and careful follow up are required. As
apixaban correlates with neither APTT nor PT, the same
clinical countermeasures should be employed based on the
clinical findings.
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